Immunotherapeutics for treating and preventing infectious diseases and cancer
Corixa was a biopharmaceutical company focusing on innovative oncology and immunology-based products. The company received FDA approval for BEXXAR, an anti-CD20 antibody conjugated to a radioactive I-131 moeity, to treat non-Hodgkin's lymphoma. Corixa also develped a novel adjuvant, MPL, that has been used in multiple investigational and approved vaccines. Corixa completed its IPO on NASDAQ in 1997 and was acquired by GSK in 2005.
